vs
Community Healthcare Trust Inc（CHCT）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Community Healthcare Trust Inc的季度营收约是REGENXBIO Inc.的1.0倍（$30.9M vs $30.3M），Community Healthcare Trust Inc净利率更高（46.6% vs -221.3%，领先268.0%），REGENXBIO Inc.同比增速更快（43.0% vs 5.6%），Community Healthcare Trust Inc自由现金流更多（$35.9M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 2.7%）
医疗物业信托（MPT）是一家总部位于美国阿拉巴马州伯明翰的国际房地产投资信托（REIT）企业，主要在美国和欧洲地区收购投资医疗设施与营利性医疗控股公司。该公司多数物业收购以售后回租形式完成：原物业所有者将物业出售给MPT后，转而成为MPT的租户，租户通常签订长期三净租赁合约。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CHCT vs RGNX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $30.9M | $30.3M |
| 净利润 | $14.4M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 46.6% | -221.3% |
| 营收同比 | 5.6% | 43.0% |
| 净利润同比 | 687.6% | -31.2% |
| 每股收益（稀释后） | $0.52 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $30.9M | $30.3M | ||
| Q3 25 | $31.1M | $29.7M | ||
| Q2 25 | $29.1M | $21.4M | ||
| Q1 25 | $30.1M | $89.0M | ||
| Q4 24 | $29.3M | $21.2M | ||
| Q3 24 | $29.6M | $24.2M | ||
| Q2 24 | $27.5M | $22.3M | ||
| Q1 24 | $29.3M | $15.6M |
| Q4 25 | $14.4M | $-67.1M | ||
| Q3 25 | $1.6M | $-61.9M | ||
| Q2 25 | $-12.6M | $-70.9M | ||
| Q1 25 | $1.6M | $6.1M | ||
| Q4 24 | $1.8M | $-51.2M | ||
| Q3 24 | $1.7M | $-59.6M | ||
| Q2 24 | $-10.4M | $-53.0M | ||
| Q1 24 | $3.7M | $-63.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
| Q4 25 | — | -190.0% | ||
| Q3 25 | — | -176.3% | ||
| Q2 25 | — | -296.3% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | — | -242.1% | ||
| Q3 24 | — | -256.6% | ||
| Q2 24 | — | -251.3% | ||
| Q1 24 | — | -408.8% |
| Q4 25 | 46.6% | -221.3% | ||
| Q3 25 | 5.3% | -208.3% | ||
| Q2 25 | -43.2% | -331.8% | ||
| Q1 25 | 5.3% | 6.8% | ||
| Q4 24 | 6.3% | -241.3% | ||
| Q3 24 | 5.9% | -246.3% | ||
| Q2 24 | -37.9% | -237.7% | ||
| Q1 24 | 12.5% | -405.4% |
| Q4 25 | $0.52 | $-1.30 | ||
| Q3 25 | $0.03 | $-1.20 | ||
| Q2 25 | $-0.50 | $-1.38 | ||
| Q1 25 | $0.03 | $0.12 | ||
| Q4 24 | $0.04 | $-0.99 | ||
| Q3 24 | $0.04 | $-1.17 | ||
| Q2 24 | $-0.42 | $-1.05 | ||
| Q1 24 | $0.11 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.3M | $230.1M |
| 总债务越低越好 | $532.2M | — |
| 股东权益账面价值 | $429.4M | $102.7M |
| 总资产 | $990.8M | $453.0M |
| 负债/权益比越低杠杆越低 | 1.24× | — |
8季度趋势，按日历期对齐
| Q4 25 | $3.3M | $230.1M | ||
| Q3 25 | $3.4M | $274.2M | ||
| Q2 25 | $4.9M | $323.3M | ||
| Q1 25 | $2.3M | $267.9M | ||
| Q4 24 | $4.4M | $234.7M | ||
| Q3 24 | $2.8M | $255.5M | ||
| Q2 24 | $734.0K | $290.4M | ||
| Q1 24 | $3.8M | $338.7M |
| Q4 25 | $532.2M | — | ||
| Q3 25 | $530.1M | — | ||
| Q2 25 | $500.1M | — | ||
| Q1 25 | $496.0M | — | ||
| Q4 24 | $486.0M | — | ||
| Q3 24 | $473.7M | — | ||
| Q2 24 | $457.6M | — | ||
| Q1 24 | $442.3M | — |
| Q4 25 | $429.4M | $102.7M | ||
| Q3 25 | $426.8M | $161.5M | ||
| Q2 25 | $437.8M | $213.7M | ||
| Q1 25 | $461.3M | $274.2M | ||
| Q4 24 | $476.0M | $259.7M | ||
| Q3 24 | $477.2M | $301.4M | ||
| Q2 24 | $497.8M | $348.3M | ||
| Q1 24 | $511.6M | $390.7M |
| Q4 25 | $990.8M | $453.0M | ||
| Q3 25 | $987.3M | $525.2M | ||
| Q2 25 | $966.3M | $581.0M | ||
| Q1 25 | $985.1M | $490.9M | ||
| Q4 24 | $992.6M | $466.0M | ||
| Q3 24 | $981.8M | $519.1M | ||
| Q2 24 | $983.2M | $569.4M | ||
| Q1 24 | $982.7M | $629.2M |
| Q4 25 | 1.24× | — | ||
| Q3 25 | 1.24× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 1.02× | — | ||
| Q3 24 | 0.99× | — | ||
| Q2 24 | 0.92× | — | ||
| Q1 24 | 0.86× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $56.4M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $35.9M | $-52.8M |
| 自由现金流率自由现金流/营收 | 116.0% | -174.0% |
| 资本支出强度资本支出/营收 | 66.3% | 1.7% |
| 现金转化率经营现金流/净利润 | 3.91× | — |
| 过去12个月自由现金流最近4个季度 | $62.8M | $-126.4M |
8季度趋势，按日历期对齐
| Q4 25 | $56.4M | $-52.3M | ||
| Q3 25 | $12.7M | $-56.0M | ||
| Q2 25 | $13.8M | $-49.3M | ||
| Q1 25 | $14.4M | $33.6M | ||
| Q4 24 | $58.9M | $-31.6M | ||
| Q3 24 | $13.8M | $-40.5M | ||
| Q2 24 | $16.7M | $-45.5M | ||
| Q1 24 | $12.6M | $-55.5M |
| Q4 25 | $35.9M | $-52.8M | ||
| Q3 25 | $7.6M | $-56.5M | ||
| Q2 25 | $9.6M | $-49.7M | ||
| Q1 25 | $9.7M | $32.6M | ||
| Q4 24 | $34.2M | $-32.7M | ||
| Q3 24 | $6.7M | $-40.9M | ||
| Q2 24 | $9.5M | $-46.0M | ||
| Q1 24 | $7.5M | $-56.0M |
| Q4 25 | 116.0% | -174.0% | ||
| Q3 25 | 24.6% | -189.9% | ||
| Q2 25 | 32.9% | -232.8% | ||
| Q1 25 | 32.3% | 36.6% | ||
| Q4 24 | 116.9% | -154.2% | ||
| Q3 24 | 22.5% | -168.9% | ||
| Q2 24 | 34.7% | -206.2% | ||
| Q1 24 | 25.7% | -358.5% |
| Q4 25 | 66.3% | 1.7% | ||
| Q3 25 | 16.3% | 1.7% | ||
| Q2 25 | 14.5% | 1.8% | ||
| Q1 25 | 15.6% | 1.2% | ||
| Q4 24 | 84.1% | 5.1% | ||
| Q3 24 | 24.2% | 1.3% | ||
| Q2 24 | 26.1% | 2.1% | ||
| Q1 24 | 17.4% | 3.6% |
| Q4 25 | 3.91× | — | ||
| Q3 25 | 7.76× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 9.06× | 5.53× | ||
| Q4 24 | 32.14× | — | ||
| Q3 24 | 7.92× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 3.45× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CHCT
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
